Publicly Traded Mid-Cap Cancer CompaniesU.S. Exchanges
List of Mid-Cap Cancer Companies
These mid-sized companies have market capitalizations between two billion and ten billion dollars. We update this page at the start of every month so it is possible that during the course of a month a company’s market cap might fall below two billion or go above ten billion. Additional cancer focused companies can be found in our Cancer Research and Treatment Companies section.
A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.
Select the company’s link to access charts, news links and company website and social media information.
Cancer: Mid-Cap Stocks
Ariad Pharmaceuticals, Inc. (ARIA) (Oncology company: chronic and acute leukemia, lung cancer and other difficult-to-treat cancers)
Exelixis, Inc. (EXEL) (Biopharmaceutical company: small molecule therapies used in the treatment of cancer)
ICU Medical, Inc. (ICUI) (Products used in critical care applications, oncology and vascular therapy)
Ionis Pharmaceuticals, Inc. (IONS) (RNA-targeted drug discovery and development: cancer, cardiovascular, metabolic, neurological disorders, rare diseases)
Juno Therapeutics, Inc. (JUNO) (Cell-based cancer immunotherapies)
Kite Pharma, Inc. (KITE) (Biopharmaceutical company: cancer immunotherapy products)
PerkinElmer, Inc. (PKI) (Electronic laboratory notebook and software, neonatal and newborn screening, cancer treatment, environmental)
Seattle Genetics, Inc. (SGEN) (Antibody-based therapies for the treatment of cancer)
Tesaro, Inc. (TSRO) (Biopharmaceutical company: oncology therapeutics and supportive care products)
Varian Medical Systems, Inc. (VAR) (Oncology treatment systems and software, X-ray products)